Suppr超能文献

G蛋白偶联受体的激动剂结合、激动剂亲和力和激动剂效能

Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.

作者信息

Strange P G

机构信息

School of Pharmacy, University of Reading, Reading, Berkshire, UK.

出版信息

Br J Pharmacol. 2008 Apr;153(7):1353-63. doi: 10.1038/sj.bjp.0707672. Epub 2008 Jan 28.

Abstract

Measurements of affinity and efficacy are fundamental for work on agonists both in drug discovery and in basic studies on receptors. In this review I wish to consider methods for measuring affinity and efficacy at G protein coupled receptors (GPCRs). Agonist affinity may be estimated in terms of the dissociation constant for agonist binding to a receptor using ligand binding or functional assays. It has, however, been suggested that measurements of affinity are always contaminated by efficacy so that it is impossible to separate the two parameters. Here I show that for many GPCRs, if receptor/G protein coupling is suppressed, experimental measurements of agonist affinity using ligand binding (K(obs)) provide quite accurate measures of the agonist microscopic dissociation constant (KA). Also in pharmacological functional studies, good estimates of agonist dissociation constants are possible. Efficacy can be quantitated in several ways based on functional data (maximal effect of the agonist (E(max)), ratio of agonist dissociation constant to concentration of agonist giving half maximal effect in functional assay (K(obs)/EC50), a combined parameter E(max)K(obs)/EC50). Here I show that E(max)K(obs)/EC50 provides the best assessment of efficacy for a range of agonists across the full range of efficacy for full to partial agonists. Considerable evidence now suggests that ligand efficacy may be dependent on the pathway used to assess it. The efficacy of a ligand may, therefore, be multidimensional. It is still, however, necessary to have accurate measures of efficacy in different pathways.

摘要

亲和力和效能的测量对于药物研发以及受体基础研究中激动剂的研究工作至关重要。在这篇综述中,我希望探讨测量G蛋白偶联受体(GPCRs)亲和力和效能的方法。激动剂亲和力可以通过使用配体结合或功能测定法来估计激动剂与受体结合的解离常数。然而,有人提出亲和力的测量总是受到效能的影响,因此无法将这两个参数分开。在这里,我表明对于许多GPCRs,如果受体/G蛋白偶联被抑制,使用配体结合(K(obs))进行激动剂亲和力的实验测量能够提供相当准确的激动剂微观解离常数(KA)的测量值。同样在药理功能研究中,也能够对激动剂解离常数进行良好的估计。效能可以基于功能数据通过几种方式进行定量(激动剂的最大效应(E(max))、激动剂解离常数与在功能测定中产生半数最大效应的激动剂浓度之比(K(obs)/EC50)、一个综合参数E(max)K(obs)/EC50)。在这里,我表明E(max)K(obs)/EC50能够对一系列激动剂在从完全激动剂到部分激动剂的整个效能范围内提供最佳的效能评估。现在有大量证据表明配体效能可能取决于用于评估它的途径。因此,配体的效能可能是多维的。然而,仍然需要在不同途径中准确测量效能。

相似文献

1
Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors.
Br J Pharmacol. 2008 Apr;153(7):1353-63. doi: 10.1038/sj.bjp.0707672. Epub 2008 Jan 28.
3
Quantifying agonist activity at G protein-coupled receptors.
J Vis Exp. 2011 Dec 26(58):e3179. doi: 10.3791/3179.
4
Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
ACS Chem Biol. 2009 Apr 17;4(4):249-60. doi: 10.1021/cb800299s. Epub 2009 Feb 4.
5
Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
Biochem Pharmacol. 2016 Feb 1;101:1-12. doi: 10.1016/j.bcp.2015.10.011. Epub 2015 Oct 23.
6
Mechanisms underlying agonist efficacy.
Biochem Soc Trans. 2007 Aug;35(Pt 4):733-6. doi: 10.1042/BST0350733.
7
Functional studies cast light on receptor states.
Trends Pharmacol Sci. 2015 Sep;36(9):596-604. doi: 10.1016/j.tips.2015.05.008. Epub 2015 Jun 26.
10
Being mindful of seven-transmembrane receptor 'guests' when assessing agonist selectivity.
Br J Pharmacol. 2010 Jul;160(5):1045-7. doi: 10.1111/j.1476-5381.2010.00764.x.

引用本文的文献

1
Quantification of signal amplification for receptors: the /EC ratio of full agonists as a gain parameter.
Front Pharmacol. 2025 Apr 8;16:1541872. doi: 10.3389/fphar.2025.1541872. eCollection 2025.
2
To activate a G protein-coupled receptor permanently with cell surface photodynamic action in the gastrointestinal tract.
World J Gastroenterol. 2025 Mar 28;31(12):102423. doi: 10.3748/wjg.v31.i12.102423.
4
Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.
Handb Exp Pharmacol. 2024;285:55-145. doi: 10.1007/164_2024_713.
7
Conformational States of the CXCR4 Inhibitor Peptide EPI-X4-A Theoretical Analysis.
Int J Mol Sci. 2023 Nov 12;24(22):16229. doi: 10.3390/ijms242216229.
8
Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.
Handb Exp Pharmacol. 2024;285:369-451. doi: 10.1007/164_2023_679.
9
Strategies to therapeutically modulate cytokine action.
Nat Rev Drug Discov. 2023 Oct;22(10):827-854. doi: 10.1038/s41573-023-00746-x. Epub 2023 Aug 4.

本文引用的文献

1
Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.
J Pharmacol Exp Ther. 2007 Jun;321(3):1193-207. doi: 10.1124/jpet.107.120857. Epub 2007 Mar 28.
3
Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity.
Annu Rev Pharmacol Toxicol. 2007;47:53-87. doi: 10.1146/annurev.pharmtox.47.120505.105126.
4
Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.
Br J Pharmacol. 2006 Oct;149(3):291-9. doi: 10.1038/sj.bjp.0706866. Epub 2006 Aug 21.
5
The receptor concept: pharmacology's big idea.
Br J Pharmacol. 2006 Jan;147 Suppl 1(Suppl 1):S9-16. doi: 10.1038/sj.bjp.0706457.
6
New concepts in drug discovery: collateral efficacy and permissive antagonism.
Nat Rev Drug Discov. 2005 Nov;4(11):919-27. doi: 10.1038/nrd1875.
7
G-protein coupled receptor assays: to measure affinity or efficacy that is the question.
Comb Chem High Throughput Screen. 2005 Jun;8(4):285-92. doi: 10.2174/1386207054020778.
8
An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor.
J Biol Chem. 2005 Apr 29;280(17):17135-41. doi: 10.1074/jbc.M414678200. Epub 2005 Feb 18.
9
Mechanisms of agonist action at D2 dopamine receptors.
Mol Pharmacol. 2004 Dec;66(6):1573-9. doi: 10.1124/mol.104.004077. Epub 2004 Aug 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验